Protara director granted options for 31,000 shares

Protara Therapeutics director Jane Huang received a stock option grant for 31,000 shares of common stock.

Rhea-AI Filing Summary

Protara Therapeutics director Jane Huang received a stock option grant for 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036. The entire Annual Grant vests on the first anniversary of the June 15, 2026 grant date, subject to her continued board service, and also fully vests upon a Change of Control.

Insider Trade Summary

Grant/Award: 31,000 shares

Grant/Award 1 txn

Insider Huang Jane

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	31,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 31,000 contracts (Direct)

Footnotes (1)

1. F1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Key Figures

Option grant size: 31,000 shares Exercise price: $3.94 per share Expiration date: June 14, 2036 +2 more

5 metrics

Option grant size 31,000 shares Stock Option (Right to Buy) granted to director Jane Huang

Exercise price $3.94 per share Conversion or exercise price of stock option grant

Expiration date June 14, 2036 Option expiration for the 31,000-share grant

Shares underlying options 31,000 shares Underlying common stock for the derivative award

Post-grant derivative holdings 31,000 options Total derivative securities following this transaction

Key Terms

Stock Option (Right to Buy), Annual Grant, Change of Control

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Annual Grant financial

"The shares subject to the Annual Grant will vest in full"

Change of Control financial

"and will vest in full upon a Change of Control."

A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Protara Therapeutics (TARA) director Jane Huang report in this Form 4?

Jane Huang reported receiving a stock option grant for 31,000 shares of Protara Therapeutics common stock. This is a compensation-related award, not an open-market purchase or sale of existing shares.

What are the key terms of Jane Huang’s Protara (TARA) stock option grant?

The grant covers 31,000 shares of common stock with a $3.94 exercise price per share. The options expire on June 14, 2036, giving a long-term window to exercise the award.

When do Jane Huang’s Protara Therapeutics (TARA) options vest?

The options from the Annual Grant vest in full on the first anniversary of the June 15, 2026 grant date. Vesting requires continuous service as a board member through that date.

How does a Change of Control affect Jane Huang’s Protara (TARA) option grant?

The footnote states the 31,000-share Annual Grant will vest in full upon a Change of Control. This means all options become fully vested if such a corporate event occurs.

Is Jane Huang’s Form 4 transaction a market buy or sell of Protara (TARA) shares?

No, this filing reports a grant of stock options, classified as a derivative acquisition. It is a compensation-related award, not an open-market purchase or sale of Protara shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/16/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Huang Jane

(Last) (First) (Middle)

C/O PROTARA THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, 3RD FLOOR

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protara Therapeutics, Inc. [ TARA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.94	06/15/2026		A		31,000		06/15/2027(1)	06/14/2036	Common Stock	31,000	$0	31,000	D

Explanation of Responses:

1. 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.

Remarks:

	/s/ Mary Grendell, Attorney-in-fact	06/16/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)